Trillium Asset Management LLC Has $7.52 Million Position in Shire PLC (SHPG)
Trillium Asset Management LLC lifted its stake in shares of Shire PLC (NASDAQ:SHPG) by 2.3% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 49,083 shares of the biopharmaceutical company’s stock after purchasing an additional 1,082 shares during the quarter. Trillium Asset Management LLC’s holdings in Shire PLC were worth $7,517,000 as of its most recent SEC filing.
Several other large investors also recently added to or reduced their stakes in SHPG. BlackRock Inc. raised its stake in shares of Shire PLC by 4,217.7% during the 1st quarter. BlackRock Inc. now owns 1,433,475 shares of the biopharmaceutical company’s stock valued at $249,755,000 after purchasing an additional 1,400,275 shares during the period. Janus Henderson Group PLC raised its stake in shares of Shire PLC by 22,560.3% during the 2nd quarter. Janus Henderson Group PLC now owns 1,286,881 shares of the biopharmaceutical company’s stock valued at $212,683,000 after purchasing an additional 1,281,202 shares during the period. Glenview Capital Management LLC raised its stake in shares of Shire PLC by 69.7% during the 2nd quarter. Glenview Capital Management LLC now owns 1,722,977 shares of the biopharmaceutical company’s stock valued at $284,756,000 after purchasing an additional 707,500 shares during the period. Northern Trust Corp raised its stake in shares of Shire PLC by 45.5% during the 2nd quarter. Northern Trust Corp now owns 1,307,339 shares of the biopharmaceutical company’s stock valued at $216,064,000 after purchasing an additional 408,843 shares during the period. Finally, OZ Management LP bought a new stake in shares of Shire PLC during the 2nd quarter valued at $57,614,000. Institutional investors own 19.24% of the company’s stock.
WARNING: This report was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another domain, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this report can be accessed at https://www.thecerbatgem.com/2017/11/07/trillium-asset-management-llc-has-7-52-million-position-in-shire-plc-shpg.html.
A number of analysts recently issued reports on SHPG shares. Royal Bank Of Canada set a $213.00 price objective on Shire PLC and gave the company a “buy” rating in a research note on Friday, August 4th. Stifel Nicolaus reiterated a “buy” rating and set a $245.00 price objective on shares of Shire PLC in a research note on Wednesday, July 12th. Cantor Fitzgerald set a $222.00 price objective on Shire PLC and gave the company a “buy” rating in a research note on Tuesday, July 11th. BTIG Research reiterated a “buy” rating and set a $242.00 price objective on shares of Shire PLC in a research note on Monday, July 17th. Finally, FBR & Co initiated coverage on Shire PLC in a research note on Thursday, October 19th. They issued a “buy” rating and a $201.00 target price on the stock. One analyst has rated the stock with a sell rating, nine have given a hold rating and twelve have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $211.00.
Shire PLC (NASDAQ SHPG) traded up $0.75 on Tuesday, hitting $146.19. The stock had a trading volume of 625,046 shares, compared to its average volume of 1,040,000. Shire PLC has a 1 year low of $137.80 and a 1 year high of $192.64. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.98 and a quick ratio of 0.52. The stock has a market cap of $43,950.00, a PE ratio of 10.05, a P/E/G ratio of 0.81 and a beta of 1.60.
Shire PLC (NASDAQ:SHPG) last posted its quarterly earnings data on Friday, October 27th. The biopharmaceutical company reported $3.81 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.64 by $0.17. Shire PLC had a return on equity of 14.41% and a net margin of 10.95%. The firm had revenue of $3.70 billion during the quarter. During the same quarter in the previous year, the company posted $3.17 earnings per share. Shire PLC’s revenue for the quarter was up 7.1% compared to the same quarter last year. research analysts expect that Shire PLC will post 15 EPS for the current fiscal year.
The business also recently announced a semiannual dividend, which was paid on Friday, October 20th. Investors of record on Friday, September 8th were issued a dividend of $0.1527 per share. This represents a yield of 0.21%. The ex-dividend date was Thursday, September 7th. Shire PLC’s dividend payout ratio is presently 17.33%.
Shire PLC Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Want to see what other hedge funds are holding SHPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Shire PLC (NASDAQ:SHPG).
Receive News & Stock Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related stocks with our FREE daily email newsletter.